Riboflavin and MTHFR: The Upstream FAD Cofactor Your Methylation Stack May Not Cover

In short: The MTHFR enzyme cannot do its job without FAD, a coenzyme the body builds from vitamin B2 (riboflavin). Methylfolate and methylcobalamin sit downstream of the MTHFR step and supply no riboflavin, so a methylation protocol can be thorough on the activated folate and B12 forms and still leave the upstream riboflavin cofactor unaddressed. BioActive Vitamin B2™ supplies 400mg of riboflavin in the activated riboflavin-5’-phosphate form, paired with magnesium (a cofactor for the enzyme that builds FAD from riboflavin) and D-ribose (energy-substrate support).*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

You’ve done the genetic testing. Read the research. Joined the Facebook groups. Built the methylation stack your practitioner recommended: methylfolate, methylcobalamin, maybe some TMG. Months of being consistent and invested. And you’re still wondering whether one part of the pathway is under-supported.

That isn’t necessarily a protocol failure. It might be a formulation gap.

BioActive Vitamin B2™  supplies riboflavin, the nutrient precursor of FAD, a cofactor the MTHFR enzyme uses in normal folate metabolism.* Here's the piece that's easy to miss: the MTHFR enzyme depends on FAD (which the body makes from vitamin B2) to do its job in the methylation pathway. Riboflavin needs are individual, and some people choose to support riboflavin status specifically. Downstream methylated vitamins like methylfolate and methylcobalamin don’t supply riboflavin, so a stack can be thorough on the downstream steps and still leave the upstream cofactor under-addressed.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

In the methylation pathway, the MTHFR enzyme requires FAD, derived from vitamin B2, as a cofactor to help convert methylenetetrahydrofolate to methylfolate. In laboratory studies of the recombinant enzyme, the common 677C→T variant protein more readily loses its FAD cofactor (Yamada et al., 2001), which is one reason riboflavin status is of interest here. BioActive Vitamin B2™ delivers 400mg of riboflavin (as Riboflavin-5’-Phosphate) through the Tri-Cofactor Activation System, providing riboflavin already in its phosphorylated coenzyme form rather than the non-phosphorylated form the body has to phosphorylate first. What the research on riboflavin and homocysteine has found, and in which populations, is described in the research section below rather than presented as a product claim.

How the Tri-Cofactor Activation System Supports the FAD Cofactor Step

This formula supplies riboflavin in its activated form at 400mg — the amount used in published human riboflavin research — paired with the cofactors involved in converting it to FAD.

BioActive Vitamin B2™ is an activated riboflavin supplement developed by Triquetra Health. The formula pairs 400mg of riboflavin (as Riboflavin-5’-Phosphate) with 50mg elemental magnesium as bisglycinate and 500mg D-Ribose in the Tri-Cofactor Activation System. The three ingredients are included based on their individual roles in the FMN→FAD step: riboflavin as the substrate, magnesium as a cofactor for the enzyme that forms FAD, and D-ribose as a source of the ribose used in ATP. The three-ingredient combination itself has not been studied as a finished formula. The genotype-specific research behind the riboflavin rationale, including the populations it was conducted in, is summarized in the research section below.

BioActive Vitamin B2™ uses the Tri-Cofactor Activation System to provide riboflavin in its activated coenzyme form, rather than the non-phosphorylated riboflavin that the body first has to convert.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Explore the full formulation details ↓

Why an MTHFR Protocol Can Still Be Missing the Upstream Riboflavin Step

You’re not someone who gave up after one bottle. You went deep. You pulled your genetic testing results, read the report closely, learned what C677T means for your methylation pathway. You found your functional medicine doctor or naturopath. You switched to the activated forms: L-5-MTHF instead of synthetic folic acid, methylcobalamin instead of cyanocobalamin. You built the exact stack the MTHFR community recommends.

Some things felt better. Some didn’t shift the way you hoped. And you found yourself back in the Facebook groups, reading about COMT, MTRR, MTHFD1, adding a few more supplements, second-guessing your methylfolate dose, feeling the particular exhaustion of a community where every answer spawns five more questions.

Here’s a part a lot of MTHFR protocols never get to: the enzyme at the center of the conversion your genetics affect isn’t a passive bystander in your stack. It has its own nutrient requirement, a cofactor it uses to function, and that cofactor isn’t supplied by the methylfolate or methylcobalamin you’re taking downstream.

That cofactor is FAD. The body makes it from vitamin B2.

Riboflavin supplies the FAD cofactor the MTHFR enzyme uses, and that cofactor is not provided by downstream methylated vitamins. Supporting riboflavin status addresses a different step of the pathway than methylfolate and B12 do. That’s the gap this formula is built around.

The Tri-Cofactor Activation System provides riboflavin in the activated coenzyme form, rather than relying on the conversion step that non-phosphorylated riboflavin supplements ask the body to complete first.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Why Many MTHFR Supplements Focus on the Downstream Part of the Pathway

To see why a protocol might be incomplete, picture the methylation pathway the way it actually runs, upstream to downstream, not just the downstream slice that methylfolate-and-B12 formulas address.

The pathway your supplements address: Methylfolate (L-5-MTHF) + methylcobalamin → homocysteine remethylation → methionine → SAMe → methylation reactions throughout the body.

That part is correct, and it matters. Those are the downstream products the variant enzyme makes less efficiently.

The upstream step: 5,10-methylenetetrahydrofolate → MTHFR enzyme → 5-methyltetrahydrofolate (methylfolate)

This upstream conversion uses FAD as the enzymatic cofactor. In laboratory studies, the 677C→T variant enzyme more readily loses its FAD (Yamada et al., 2001). Riboflavin is the direct dietary source of that FAD cofactor, and downstream methylated vitamins don’t substitute for it.

Where a standard MTHFR stack can leave a gap

A methylation formula built around methylfolate and methylcobalamin supplies the downstream active forms. Check the riboflavin line on the label: unless it specifies riboflavin-5'-phosphate, it is the standard non-phosphorylated form, and the amount is whatever the panel discloses. Riboflavin is one part of the folate pathway that methylfolate and B12 do not supply. BioActive Vitamin B2™ centers the formula on riboflavin in its activated form (400mg as Riboflavin-5’-Phosphate) with supporting cofactors, meant to sit alongside your existing methylfolate and B12 rather than replace them.*

Standard riboflavin supplements use the non-phosphorylated form, which the body first converts (via riboflavin kinase) to FMN and then to FAD. BioActive Vitamin B2™ provides Riboflavin-5’-Phosphate, riboflavin already in its FMN coenzyme form, through the Tri-Cofactor Activation System.*

BioActive Vitamin B2™  provides 400mg of riboflavin (as Riboflavin-5’-Phosphate) with cofactor support. The body absorbs relatively little riboflavin from a single dose above roughly 27 mg (NIH ODS), and the excess is excreted in the urine, which can turn it bright yellow. The 400mg amount reflects the dose used in published human riboflavin research (Schoenen et al., 1998) rather than an absorption advantage.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The upstream piece so many MTHFR protocols overlook isn’t another methylated vitamin. It’s the riboflavin that supplies the FAD cofactor the MTHFR enzyme uses in the first place.

How Triple-Phase Cofactor Delivery Supports the FAD Step

The Tri-Cofactor Activation System comes down to a simple idea: form and cofactors both matter. It provides riboflavin in its activated form alongside the cofactors involved in the two-step FAD activation cascade, from substrate to enzyme to energy. The three ingredients are combined based on their individual mechanisms; the combination itself has not been tested as a single formula in a clinical trial.

Phase 1: Activated Substrate Delivery

Riboflavin-5’-Phosphate (548mg providing 400mg riboflavin) is supplied as FMN, the first active coenzyme form. Non-phosphorylated riboflavin has to be phosphorylated by riboflavin kinase before it can move toward FAD. R5P provides riboflavin already in its phosphorylated coenzyme form. R5P is dephosphorylated in the gut and re-phosphorylated after absorption, so the practical advantage is in the delivered coenzyme form rather than a complete bypass of the body’s own enzymes. No head-to-head human trial has compared Riboflavin-5’-Phosphate with non-phosphorylated riboflavin for riboflavin status or homocysteine; the form is chosen for the delivered coenzyme form, not on demonstrated superior absorption.

Phase 2: FAD Synthase Support via Magnesium Cofactor

FAD synthase turns FMN into FAD through the reaction FMN + ATP → FAD + PPi, and that reaction is magnesium-dependent. Magnesium bisglycinate (278mg providing 50mg elemental) is a chelated form commonly chosen for gastrointestinal comfort. It’s included here as the Mg²⁺ cofactor tied to the FAD synthase step, not as general-purpose magnesium. At 50mg elemental (about 12% of the Daily Value), it’s a modest, targeted amount rather than a full magnesium dose.

Phase 3: ATP Substrate Support via D-Ribose

Both conversion steps in the cascade use ATP. D-Ribose (500mg) enters the pentose phosphate pathway directly as ribose-5-phosphate and is proposed to contribute to the ATP pool via the pentose phosphate and salvage pathways. Thompson et al. (Journal of Clinical Pharmacology, 2014) characterized oral D-ribose pharmacokinetics (Tmax roughly 18 to 30 minutes) at doses of 2.5 to 10 g; that study does not evaluate the 500mg amount used here. D-ribose is included as a mechanistic rationale for energy-substrate support; it has not been shown in clinical trials to improve FAD synthesis, MTHFR function, or homocysteine.

Bringing It Together

FAD is the cofactor the MTHFR enzyme uses. When riboflavin status is adequate, FAD binds the enzyme and supports its role in converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (methylfolate). In normal metabolism, methylfolate enters the methylation cycle, where homocysteine is remethylated to methionine and SAMe is formed.*

The 400mg amount reflects the dose used in published riboflavin research rather than a tissue-saturation advantage, since the body absorbs relatively little riboflavin from a single dose above roughly 27 mg and excretes the rest. Riboflavin is one part of the folate pathway that downstream methylated vitamins do not supply. BioActive Vitamin B2™‘s Tri-Cofactor Activation System delivers 400mg of riboflavin (as Riboflavin-5’-Phosphate) alongside magnesium bisglycinate (a cofactor for FAD synthase) and D-Ribose (ATP-substrate support).*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Supporting Riboflavin and FAD Status Does and Doesn’t Mean

The research points to biomarker and DNA-methylation changes in a specific genotype. Here’s how to think about what supporting the FAD cofactor step does and doesn’t mean.

Riboflavin’s Role in Normal Folate Metabolism

Functional: Riboflavin is the dietary precursor of FAD, the cofactor the MTHFR enzyme uses in normal folate metabolism.*

Riboflavin’s relationship to homocysteine has been studied mainly in adults with the MTHFR 677TT genotype who had suboptimal riboflavin status and homocysteine above the usual reference range: in that population, improving riboflavin status was associated with lower homocysteine (McNulty et al., 2006, Circulation). Those findings are specific to that population and are not a claim about what the product does for people whose homocysteine is already normal. Researchers have also observed changes in DNA methylation in adults with the 677TT genotype following riboflavin supplementation (Amenyah et al., 2020, Biochimie); what those epigenetic changes mean for health outcomes has not yet been established.

The decision: There’s satisfaction in understanding your own biochemistry well enough to make a deliberate, informed choice about it, and in addressing a step of the pathway your downstream vitamins don’t cover.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Supporting Normal Energy Metabolism

Functional: Riboflavin-derived FAD and FMN participate in normal energy metabolism.* Cognitive outcomes such as focus or mental clarity have not been evaluated in riboflavin trials in this population, so this formula makes no claim about them.

The decision: Rounding out a methylation protocol with the upstream riboflavin step it may have been missing is, for a lot of people, about completeness rather than a promised feeling.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Something You Can Actually Track

Functional: Unlike effects that stay purely subjective, riboflavin status and homocysteine can be measured with standard blood testing before and after a trial period. Amenyah et al. (2020) studied DNA methylation as an additional measured outcome in adults with the 677TT genotype; DNA methylation was measured in a research setting and is not a routine clinical test.

The decision: The MTHFR community can be wearing precisely because so much of it runs on experiments without verification. Choosing something you can measure, by retesting after a comparable interval, swaps some of that uncertainty for something concrete. Interpretation of any result belongs with your healthcare provider.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What the Research Shows About Riboflavin and the MTHFR 677TT Genotype

The riboflavin rationale draws on genotype-specific research in adults with the MTHFR 677TT genotype: riboflavin status was associated with lower homocysteine (McNulty et al., Circulation 2006), and riboflavin supplementation altered DNA methylation in the same genotype (Amenyah et al., Biochimie 2020).

Primary Study: McNulty et al. (2006)

A randomized, placebo-controlled, genotype-stratified trial found that improving riboflavin status (using 1.6 mg/day riboflavin) was associated with lower homocysteine specifically in 677TT homozygotes, by about 22% overall and more in those with lower baseline riboflavin status, with no homocysteine response in either the CC (wild-type) or CT (heterozygous) groups, despite all three genotype groups being preselected for suboptimal riboflavin status (McNulty et al., Circulation, 113(1), 74-80). Two things are worth keeping in view. First, the effect was genotype-specific, which points at the FAD-cofactor mechanism. Second, participants were preselected for suboptimal riboflavin status and began with homocysteine concentrations above the usual reference range (roughly 16 µmol/L overall, higher in the low-riboflavin subgroup), in a country without folic-acid fortification. Results in people whose riboflavin status and homocysteine are already normal may differ. Also worth noting: the dose studied was 1.6 mg/day, far below this product’s 400mg.

Secondary Study: Amenyah et al. (2020)

A randomized trial in adults with the MTHFR 677TT genotype reported that riboflavin supplementation altered global and gene-specific DNA methylation, including a small reduction (about 1.2%) in methylation at an MTHFR regulatory region (Amenyah et al., Biochimie, 173, 17-26). This is a directional epigenetic change; what it means for health outcomes has not yet been established. It’s included as mechanistic context, not as a demonstrated benefit.

Published Human Dosing Precedent: Schoenen et al. (1998)

A randomized, double-blind, placebo-controlled trial administered 400mg riboflavin daily for three months (Schoenen et al., Neurology, 50(2), 466-470). It is cited here only as a precedent that 400mg/day of riboflavin has been given in published human research for up to three months without reported adverse effects. It studied a different use and is not evidence of any benefit for the purposes of this product.

What the Evidence Does and Doesn’t Show

The riboflavin-homocysteine relationship appears to depend on genotype and on baseline riboflavin and folate status, and not every study finds a homocysteine effect. In a 12-week randomized trial in older adults preselected for suboptimal riboflavin status, 1.6 mg/day riboflavin significantly improved riboflavin status but did not change homocysteine (P = 0.719), while folic acid in the same trial lowered it by about 20% (McKinley et al., 2002). In a further analysis of riboflavin-supplemented adults with the 677TT genotype, participants drawn from earlier trials in treated hypertensive adults, S-adenosylmethionine and cystathionine increased while other one-carbon metabolites did not change (Rooney et al., 2020). And cross-sectional data in 423 healthy adults found plasma riboflavin to be an independent determinant of homocysteine, with the relationship largely confined to carriers of the 677T allele (Hustad et al., 2000). In short, the clearest signal is in 677TT individuals with suboptimal riboflavin status; the picture in people who are already replete is less clear.

The 2020 analyses (Amenyah, Rooney) draw on participants from the same riboflavin trial program as the 2006 study rather than representing independent replications.

Safety Notes

Riboflavin has no Tolerable Upper Intake Level, and no adverse effects have been reported up to 400mg/day for at least three months (IOM 1998; NIH ODS). High riboflavin intake commonly turns urine bright yellow, which is harmless. Magnesium can cause gastrointestinal effects such as loose stools in some people. D-ribose can cause transient low blood sugar and mild gastrointestinal upset, generally at doses far higher than the 500mg here; EFSA (2018) considered D-ribose safe up to 36 mg/kg body weight per day. Anyone who is pregnant or breastfeeding, or managing a medical condition or medications, should talk with their healthcare provider before starting.

What’s in Each Serving, and Why

Notes on formulation choices:

Activated form: BioActive Vitamin B2™  provides riboflavin as Riboflavin-5'-Phosphate (FMN), the activated coenzyme form.

Dose: 400mg reflects the amount used in published human riboflavin research. Because the body absorbs relatively little riboflavin from a single dose above roughly 27 mg, the higher amount is not an absorption claim.

Cofactor support: The formula pairs riboflavin with magnesium (a cofactor for FAD synthase) and D-ribose (energy-substrate support) based on their individual mechanistic roles.

How This Compares to Other Riboflavin Options

Riboflavin supplements differ mainly in the form of the vitamin and whether activation cofactors are included. The comparison below is limited to objective formulation attributes, what form is used and what is or isn't present, not to any claim about relative effectiveness:

This formula combines an activated form, the two activation cofactors described above, and fully disclosed amounts. Because the body absorbs relatively little riboflavin from a single dose above roughly 27 mg, a larger number on the label is not itself an advantage.

Your Questions About Riboflavin and the FAD Cofactor Step, Answered

Each answer below is written to stand on its own if it appears in a search result or AI overview. Where an answer carries a structure/function claim, the FDA disclaimer is included with it.

How is this different from the methylated B vitamins I'm already taking?

Methylfolate and methylcobalamin are downstream products of the MTHFR enzyme; they supply active forms your methylation cycle uses. BioActive Vitamin B2™ addresses a different step, the upstream riboflavin that the body converts to the FAD cofactor the MTHFR enzyme uses. Riboflavin is one part of the folate pathway those downstream vitamins do not supply.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

How will I know if it's working?

Riboflavin status and homocysteine can be measured by standard blood testing before you start and again after a comparable interval; that's the objective way to track any change, and interpretation belongs with your healthcare provider.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Do I stop taking my methylfolate and B12?

No. BioActive Vitamin B2™  is meant to work alongside your existing methylation protocol, not replace it.* Keep your methylfolate and B12 at their current doses and check with your healthcare provider about your individual protocol.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Is this safe with my medications?

Riboflavin has no established Upper Intake Level, and magnesium bis-glycinate is generally well tolerated at 50mg elemental. In laboratory and animal research, some medications, including certain phenothiazines and tricyclic antidepressants, have been reported to affect enzymes involved in riboflavin activation; whether this matters clinically in people has not been established. Talk with your healthcare provider about your specific medications before adding any supplement.

Add the Upstream Riboflavin Step to Your Methylation Routine

BioActive Vitamin B2™ supplies riboflavin, the precursor of the FAD cofactor the MTHFR enzyme uses, in an activated form with supporting cofactors, meant to sit alongside your existing methylfolate and methylcobalamin.* Riboflavin is one part of the folate pathway those downstream vitamins do not supply.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Learn More About BioActive Vitamin B2™  

Backed by our 60-day money-back guarantee.

For the Detail-Oriented: Complete Ingredient Documentation

Riboflavin-5'-Phosphate (R5P/FMN), 548mg providing 400mg riboflavin

What it is: R5P is the phosphorylated form of riboflavin, existing as Flavin Mononucleotide (FMN), the first active coenzyme in the B2 activation cascade. The USP monograph for riboflavin 5'-phosphate sodium specifies a riboflavin content of 73.0% to 79.0% by weight on the dried basis, so 548mg of compendial-grade material supplies at least 400mg of riboflavin.

Conversion profile: By supplying FMN, R5P provides riboflavin already past the riboflavin kinase step (riboflavin + ATP → FMN). R5P is dephosphorylated in the gut and re-phosphorylated after absorption, so the practical benefit is the activated coenzyme form delivered, not a total bypass of the body's own enzymes.

Context: Riboflavin was studied at 1.6 mg/day in McNulty et al. (Circulation 2006) for genotype-specific homocysteine differences and at 400mg/day for three months in Schoenen et al. (Neurology 1998) as a dosing/tolerability precedent. Amenyah et al. (2020) reported DNA methylation changes in the MTHFR 677TT genotype.

Safety: Riboflavin-5'-phosphate sodium is affirmed as generally recognized as safe for use as a nutrient supplement (21 CFR 184.1697). No Upper Intake Level has been established. No adverse effects have been documented from 400mg/day for at least three months. Water-soluble; excess is excreted (which can turn urine bright yellow).

Magnesium Bis-glycinate, 278mg providing 50mg elemental magnesium

What it is: Magnesium chelated to two glycine molecules, a form commonly chosen for gastrointestinal comfort.

Cofactor role: Magnesium serves as the Mg²⁺ cofactor for FAD synthase, which catalyzes FMN + ATP → FAD + PPi. It's included as targeted cofactor support for the FAD synthesis step.

Absorption context: Absorption comparisons between magnesium forms vary between studies; magnesium oxide has been measured at roughly 4% fractional absorption (Firoz & Graber, 2001). Head-to-head human evidence specifically for bis-glycinate is limited.

Safety: Magnesium bis-glycinate is a lawfully marketed dietary ingredient. The chelated form is associated with fewer gastrointestinal effects than some inorganic magnesium salts; magnesium can still cause loose stools in some people.

D-Ribose, 500mg (≥98% purity)

What it is: A five-carbon pentose sugar that forms part of ATP, ADP, AMP, NAD+/NADH, and FAD/FADH2. It enters the pentose phosphate pathway directly as ribose-5-phosphate.

Rationale for inclusion: The FAD synthesis step (FMN + ATP → FAD) uses ATP. D-ribose is included as mechanistic support for the ATP pool. It has not been shown in clinical trials to improve FAD synthesis, MTHFR function, or homocysteine.

Context: Thompson et al. (Journal of Clinical Pharmacology, 2014) characterized oral D-ribose pharmacokinetics (Tmax roughly 18 to 30 minutes) at doses of 2.5 to 10 g; this does not evaluate the 500mg amount used here.

Safety: D-ribose is the subject of FDA GRAS Notice GRN 243, for which FDA responded with no questions (conditioned on use alongside an additional carbohydrate energy source). EFSA (2018) considered it safe up to 36 mg/kg body weight per day. It can cause transient hypoglycemia and mild gastrointestinal upset, generally at doses far above 500mg.

MTHFR Variant Types and Riboflavin

MTHFR variants are common and, per the CDC, considered a normal part of human genetic variation. The notes below are educational, not an indication for any product.

677C→T Heterozygous (one copy): Associated with moderately reduced enzyme activity (roughly 35% lower per variant allele in laboratory studies; Yamada et al., 2001). Carrying one copy (the CT genotype) is more common than carrying two.

677C→T Homozygous (two copies, "TT"): Associated with more substantially reduced enzyme activity; in laboratory studies the variant enzyme more readily loses FAD (Yamada et al., 2001). In U.S. population estimates, the TT genotype is found in about 11.5% of non-Hispanic white adults, 19.9% of Mexican American adults, and 1.2% of non-Hispanic Black adults (CDC, U.S. Genome Variation Estimates). This is the genotype studied in McNulty et al. (2006) and Amenyah et al. (2020).

A1298C Variant: Affects a different region of the enzyme. Evidence for a riboflavin effect in A1298C-only carriers is less established than for C677T. Compound heterozygosity is more complex; discuss protocol questions with a genetics-aware practitioner.

Extended FAQ

Can I take this if I have COMT variants?

COMT variants affect a methylation enzyme separate from the riboflavin/FAD step this product addresses.* Because the methylation pathway is interconnected, discuss sequencing and dosing with your healthcare provider, ideally one familiar with genetic-variant interactions.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What if I have both MTHFR and MTRR variants?

MTRR affects a separate step from the MTHFR riboflavin/FAD requirement.* Having both variants makes for a more complex picture; a genetics-aware practitioner can help with a full assessment.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

How does this interact with my methylfolate dose?

This product addresses an upstream step and is not a reason to change your methylfolate dose on its own.* Work with your provider, and consider retesting after a comparable interval before making changes.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

When should I retest?

The trials discussed here ran 12 to 16 weeks. Baseline testing before starting, with retesting after a comparable interval, gives the clearest read.* Interpretation belongs with your healthcare provider.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Can I use this during pregnancy?

Riboflavin status matters in pregnancy, but supplementation should be individualized with medical guidance. Consult your obstetrician or midwife before starting or continuing any supplement during pregnancy or while breastfeeding.

What's the difference between this and high-dose riboflavin from a pharmacy?

Unless the label specifies riboflavin-5'-phosphate, pharmacy riboflavin is the standard non-phosphorylated form, and a single-ingredient riboflavin product does not include magnesium or D-ribose cofactor support. BioActive Vitamin B2™  provides the activated R5P form alongside those cofactors.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Scientific References & Citations

All sources are listed with DOI or PubMed links.

Peer-Reviewed Studies

Amenyah, S. D., McMahon, A., Ward, M., Deane, J., McNulty, H., Hughes, C. F., Strain, J. J., Horigan, G., Purvis, J., Walsh, C. P., & Lees-Murdock, D. J. (2020). Riboflavin supplementation alters global and gene-specific DNA methylation in adults with the MTHFR 677 TT genotype. Biochimie, 173, 17-26. https://doi.org/10.1016/j.biochi.2020.04.007 (PMID: 32334045). Relevance: RCT evidence that riboflavin alters DNA methylation in the 677TT genotype; directional change of not-yet-established clinical meaning.

Firoz, M., & Graber, M. (2001). Bioavailability of US commercial magnesium preparations. Magnesium Research, 14(4), 257-262. https://pubmed.ncbi.nlm.nih.gov/11794633/ Relevance: Source for the ~4% fractional absorption figure for magnesium oxide.

Hustad, S., Ueland, P. M., Vollset, S. E., Zhang, Y., Bjørke-Monsen, A. L., & Schneede, J. (2000). Riboflavin as a determinant of plasma total homocysteine: Effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clinical Chemistry, 46(8 Pt 1), 1065-1071. https://pubmed.ncbi.nlm.nih.gov/10926884/ Relevance: Cross-sectional data (423 healthy adults); plasma riboflavin an independent determinant of homocysteine, largely confined to 677T-allele carriers (balance).

McKinley, M. C., McNulty, H., McPartlin, J., Strain, J. J., Weir, D. G., & Scott, J. M. (2002). Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status. European Journal of Clinical Nutrition, 56(9), 850-856. https://doi.org/10.1038/sj.ejcn.1601402 Relevance: 12-week RCT; riboflavin improved riboflavin status but did not change homocysteine (P = 0.719); folic acid in the same trial lowered it ~20% (balance/null result).

McNulty, H., Dowey, L. R. C., Strain, J. J., Dunne, A., Ward, M., Molloy, A. M., McAnena, L. B., Hughes, J. P., Hannon-Fletcher, M., & Scott, J. M. (2006). Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C→T polymorphism. Circulation, 113(1), 74-80. https://doi.org/10.1161/CIRCULATIONAHA.105.580332 (PMID: 16380544). Relevance: Primary genotype-stratified evidence; participants preselected for suboptimal riboflavin status with above-range baseline homocysteine; dose 1.6 mg/day.

Rooney, M., Bottiglieri, T., Wasek-Patterson, B., McMahon, A., Hughes, C. F., McCann, A., Horigan, G., Strain, J. J., McNulty, H., & Ward, M. (2020). Impact of the MTHFR C677T polymorphism on one-carbon metabolites: Evidence from a randomised trial of riboflavin supplementation. Biochimie, 173, 91-99. https://doi.org/10.1016/j.biochi.2020.04.004 (PMID: 32330571). Relevance: In 677TT adults (drawn from prior blood-pressure trials), SAM and cystathionine increased with riboflavin; other one-carbon metabolites unchanged (balance/context).

Schoenen, J., Jacquy, J., & Lenaerts, M. (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology, 50(2), 466-470. https://doi.org/10.1212/wnl.50.2.466 (PMID: 9484373). Relevance: Cited only as a published human dosing/tolerability precedent for 400mg/day over three months.

Thompson, J., Neutel, J., Homer, K., Tempero, K., Shah, A., & Khankari, R. (2014). Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects. Journal of Clinical Pharmacology, 54(5), 546-554. https://doi.org/10.1002/jcph.241 (PMID: 24272966). Relevance: D-ribose pharmacokinetics (Tmax ~18-30 min) at 2.5-10 g; does not evaluate the 500mg amount used here.

Yamada, K., Chen, Z., Rozen, R., & Matthews, R. G. (2001). Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proceedings of the National Academy of Sciences, 98(26), 14853-14858. https://doi.org/10.1073/pnas.261469998 (PMID: 11742092). Relevance: Laboratory source for the variant enzyme's tendency to lose FAD, and ~35% activity loss per variant allele.

Regulatory & Safety Documentation

U.S. Pharmacopeia. Riboflavin 5′-Phosphate Sodium (USP-NF monograph M73550). https://doi.usp.org/USPNF/USPNF_M73550_01_01.html Relevance: Compendial specification of 73.0% to 79.0% riboflavin content on the dried basis, the basis for 548mg R5P supplying at least 400mg riboflavin.

Centers for Disease Control and Prevention. MTHFR allele and genotype frequencies, U.S. Genome Variation Estimates. https://archive.cdc.gov/www_cdc_gov/genomics/population/genvar/frequencies/mthfr.htm Relevance: U.S. population genotype prevalence estimates for MTHFR C677T (rs1801133) by race-ethnicity.

U.S. Food and Drug Administration. Riboflavin-5′-phosphate (sodium), 21 C.F.R. § 184.1697. https://www.law.cornell.edu/cfr/text/21/184.1697 Relevance: GRAS affirmation for R5P sodium.

U.S. Food and Drug Administration. GRAS Notice Inventory, GRN No. 243 (D-ribose). https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=grasnotices&id=243 Relevance: FDA "no questions" response for D-ribose.

European Food Safety Authority. (2018). Safety of D-ribose as a novel food. EFSA Journal. https://www.efsa.europa.eu/en/efsajournal/pub/5265 Relevance: Safety assessment (up to 36 mg/kg bw/day); a safety, not a bioavailability, evaluation.

Institute of Medicine, Food and Nutrition Board. (1998). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academy Press. https://www.ncbi.nlm.nih.gov/books/NBK114322/ Relevance: No Tolerable Upper Intake Level established for riboflavin; water-soluble safety profile. (The ~27 mg single-dose absorption figure is attributed by NIH ODS to Zempleni et al., 1996.)

National Institutes of Health, Office of Dietary Supplements. (2022). Riboflavin: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/ Relevance: RDA, the ~27 mg single-dose absorption figure (attributed by ODS to Zempleni et al., 1996), and safety reference.

Centers for Disease Control and Prevention. MTHFR gene, folic acid, and preventing neural tube defects. https://www.cdc.gov/folic-acid/data-research/mthfr/index.html Relevance: Source for the statement that MTHFR variants are common and normal.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.